BACKGROUND: The authors investigated the hypothesis that isoflurane modulates nitric oxide (NO) synthesis and protection against myocardial infarction through time-dependent changes in expression of key NO regulatory proteins, guanosine triphosphate cyclohydrolase (GTPCH)-1, the rate-limiting enzyme involved in the biosynthesis of tetrahydrobiopterin and endothelial nitric oxide synthase (eNOS). METHODS: Myocardial infarct size, NO production (ozone-mediated chemiluminescence), GTPCH-1, and eNOS expression (real-time reverse transcriptase polymerase chain reaction and western blotting) were measured in male Wistar rats with or without anesthetic preconditioning (APC; 1.0 minimum alveolar concentration isoflurane for 30 min) and in the presence or absence of an inhibitor of GTPCH-1, 2,4-diamino-6-hydroxypyrimidine. RESULTS: NO2 production (158 ± 16 and 150 ± 13 pmol/mg protein at baseline in control and APC groups, respectively) was significantly (P < 0.05) increased 1.5 ± 0.1 and 1.4 ± 0.1 fold by APC (n = 4) at 60 and 90 min of reperfusion, respectively, concomitantly, with increased expression of GTPCH-1 (1.3 ± 0.3 fold; n = 5) and eNOS (1.3 ± 0.2 fold; n = 5). In contrast, total NO (NO2 and NO3) was decreased after reperfusion in control experiments. Myocardial infarct size was decreased (43 ± 2% of the area at risk for infarction; n = 6) by APC compared with control experiments (57 ± 1%; n = 6). 2, 4-Diamino-6-hydroxypyrimidine decreased total NO production at baseline (221 ± 25 and 175 ± 31 pmol/mg protein at baseline in control and APC groups, respectively), abolished isoflurane-induced increases in NO at reperfusion, and prevented reductions of myocardial infarct size by APC (60 ± 2%; n = 6). CONCLUSION: APC favorably modulated a NO biosynthetic pathway by up-regulating GTPCH-1 and eNOS, and this action contributed to protection of myocardium against ischemia and reperfusion injury.
BACKGROUND: The authors investigated the hypothesis that isoflurane modulates nitric oxide (NO) synthesis and protection against myocardial infarction through time-dependent changes in expression of key NO regulatory proteins, guanosine triphosphate cyclohydrolase (GTPCH)-1, the rate-limiting enzyme involved in the biosynthesis of tetrahydrobiopterin and endothelial nitric oxide synthase (eNOS). METHODS:Myocardial infarct size, NO production (ozone-mediated chemiluminescence), GTPCH-1, and eNOS expression (real-time reverse transcriptase polymerase chain reaction and western blotting) were measured in male Wistar rats with or without anesthetic preconditioning (APC; 1.0 minimum alveolar concentration isoflurane for 30 min) and in the presence or absence of an inhibitor of GTPCH-1, 2,4-diamino-6-hydroxypyrimidine. RESULTS:NO2 production (158 ± 16 and 150 ± 13 pmol/mg protein at baseline in control and APC groups, respectively) was significantly (P < 0.05) increased 1.5 ± 0.1 and 1.4 ± 0.1 fold by APC (n = 4) at 60 and 90 min of reperfusion, respectively, concomitantly, with increased expression of GTPCH-1 (1.3 ± 0.3 fold; n = 5) and eNOS (1.3 ± 0.2 fold; n = 5). In contrast, total NO (NO2 and NO3) was decreased after reperfusion in control experiments. Myocardial infarct size was decreased (43 ± 2% of the area at risk for infarction; n = 6) by APC compared with control experiments (57 ± 1%; n = 6). 2, 4-Diamino-6-hydroxypyrimidine decreased total NO production at baseline (221 ± 25 and 175 ± 31 pmol/mg protein at baseline in control and APC groups, respectively), abolished isoflurane-induced increases in NO at reperfusion, and prevented reductions of myocardial infarct size by APC (60 ± 2%; n = 6). CONCLUSION: APC favorably modulated a NO biosynthetic pathway by up-regulating GTPCH-1 and eNOS, and this action contributed to protection of myocardium against ischemia and reperfusion injury.
Authors: Zhi-Dong Ge; Danijel Pravdic; Martin Bienengraeber; Phillip F Pratt; John A Auchampach; Garrett J Gross; Judy R Kersten; David C Warltier Journal: Anesthesiology Date: 2010-01 Impact factor: 7.892
Authors: Zhi-Dong Ge; Irina A Ionova; Nikolina Vladic; Danijel Pravdic; Naoyuki Hirata; Jeannette Vásquez-Vivar; Phillip F Pratt; David C Warltier; Galen M Pieper; Judy R Kersten Journal: Cardiovasc Res Date: 2011-03-21 Impact factor: 10.787
Authors: Thorsten M Leucker; Martin Bienengraeber; Maria Muravyeva; Ines Baotic; Dorothee Weihrauch; Anna K Brzezinska; David C Warltier; Judy R Kersten; Phillip F Pratt Journal: J Mol Cell Cardiol Date: 2011-07-21 Impact factor: 5.000
Authors: Julien Amour; Anna K Brzezinska; Zachary Jager; Corbin Sullivan; Dorothee Weihrauch; Jianhai Du; Nikolina Vladic; Yang Shi; David C Warltier; Phillip F Pratt; Judy R Kersten Journal: Anesthesiology Date: 2010-03 Impact factor: 7.892
Authors: Asli F Ceylan-Isik; Kelly K Guo; Edward C Carlson; Jamie R Privratsky; Song-Jie Liao; Lu Cai; Alex F Chen; Jun Ren Journal: Hypertension Date: 2009-04-27 Impact factor: 10.190
Authors: Weidong Gu; Franz Kehl; John G Krolikowski; Paul S Pagel; David C Warltier; Judy R Kersten Journal: Anesthesiology Date: 2008-04 Impact factor: 7.892
Authors: Yanan Liu; Mark Paterson; Shelley L Baumgardt; Michael G Irwin; Zhengyuan Xia; Zeljko J Bosnjak; Zhi-Dong Ge Journal: Cardiovasc Res Date: 2019-01-01 Impact factor: 10.787
Authors: Yanan Liu; Shelley L Baumgardt; Juan Fang; Yang Shi; Shigang Qiao; Zeljko J Bosnjak; Jeannette Vásquez-Vivar; Zhengyuan Xia; David C Warltier; Judy R Kersten; Zhi-Dong Ge Journal: Sci Rep Date: 2017-06-08 Impact factor: 4.379
Authors: Hsiang-En Wu; Shelley L Baumgardt; Juan Fang; Mark Paterson; Yanan Liu; Jianhai Du; Yang Shi; Shigang Qiao; Zeljko J Bosnjak; David C Warltier; Judy R Kersten; Zhi-Dong Ge Journal: Sci Rep Date: 2016-06-13 Impact factor: 4.379